Torricelli Andre A M, Santhanam Abirami, Agrawal Vandana, Wilson Steven E
Cole Eye Institute, Cleveland Clinic, Cleveland, OH.
Mol Vis. 2014 Dec 23;20:1710-6. eCollection 2014.
To perform a masked study to determine whether resolvin E1 (RvE1), a lipid-derived immunomodulator, could regulate the development of corneal haze and opacity-related myofibroblasts after opacity-generating high correction photorefractive keratectomy (PRK) in rabbits.
Three groups of eight rabbits each were included in the study. Nine diopter (D) PRK for myopia was performed in each test cornea, and the eyes were treated with 30 µl of topical solution every 4 h (six times a day) for 5 days starting immediately after PRK. Group 1 was treated with 0.1% RX-10045, a prodrug of an RvE1 analog; group 2 was treated with 0.01% RX-10045; and group 3 was treated with vehicle control solution. At 1 month after PRK, haze was graded at the slit-lamp by a masked observer. Immunohistochemistry for α-smooth muscle actin (SMA) was performed on the central cornea of each test eye to determine the anterior stromal myofibroblast density.
Corneal opacity was significantly lower in the 0.1% RX-10045 group, but not the 0.01% RX-10045 group, compared to the vehicle control group (p=0.029), at 1 month after -9.0D PRK. At 1 month after -9.0D PRK, SMA+ myofibroblast densities in the anterior stroma were not statistically significantly different among the three groups, although a trend toward lower myofibroblast generation was noted in the 0.1% RX-10045 group.
Topical 0.1% RX-10045, a prodrug of an RvE1 analog, reduces corneal opacity after haze-generating PRK in rabbits. Further studies are needed to determine the precise points at which RvE1 decreases corneal opacity after injury.
进行一项双盲研究，以确定脂质衍生的免疫调节剂消退素E1（RvE1）是否能在兔致混浊性高度矫正准分子激光原位角膜磨镶术（PRK）后调节角膜混浊和与混浊相关的肌成纤维细胞的发育。
该研究纳入三组，每组8只兔子。对每只受试角膜进行9屈光度（D）的近视PRK手术，并在PRK术后立即开始，每4小时（每天6次）用30微升局部溶液处理眼睛，持续5天。第1组用0.1% RX - 10045（RvE1类似物的前药）处理；第2组用0.01% RX - 10045处理；第3组用赋形剂对照溶液处理。PRK术后1个月，由一位双盲观察者在裂隙灯下对混浊进行分级。对每只受试眼的中央角膜进行α - 平滑肌肌动蛋白（SMA）免疫组织化学检测，以确定前基质肌成纤维细胞密度。
在-9.0D PRK术后1个月，与赋形剂对照组相比，0.1% RX - 10045组的角膜混浊明显更低，但0.01% RX - 10045组并非如此（p = 0.029）。在-9.0D PRK术后1个月，尽管在0.1% RX - 10045组中观察到肌成纤维细胞生成有降低趋势，但三组前基质中SMA + 肌成纤维细胞密度在统计学上无显著差异。
局部应用0.1% RX - 10045（RvE1类似物的前药）可降低兔致混浊性PRK术后的角膜混浊。需要进一步研究以确定RvE1在损伤后降低角膜混浊的确切作用点。
